Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition

SGLT2i reduce cardiac hypertrophy, but underlying mechanisms remain unknown. Here we explore a role for serine/threonine kinases (STK) and sodium hydrogen exchanger 1(NHE1) activities in SGLT2i effects on cardiac hypertrophy. Isolated hearts from db/db mice were perfused with 1 µM EMPA, and STK phos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomedicine & pharmacotherapy 2024-05, Vol.174, p.116477-116477, Article 116477
Hauptverfasser:	Chen, Sha, Overberg, Kenneth, Ghouse, Zakiya, Hollmann, Markus W., Weber, Nina C., Coronel, Ruben, Zuurbier, Coert J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Aurora Benzhydryl Compounds - pharmacology Cardiomegaly - drug therapy Cardiomegaly - metabolism Cardiomegaly - pathology Cardiomegaly - prevention & control Cell Line FoxO pathways Glucosides - pharmacology hypertrophy Male Mice Mice, Inbred C57BL Myocytes, Cardiac - drug effects Myocytes, Cardiac - metabolism Myocytes, Cardiac - pathology p90 ribosomal S6 Kinase (RSK) Phosphorylation - drug effects Rats Ribosomal Protein S6 Kinases, 90-kDa - antagonists & inhibitors Ribosomal Protein S6 Kinases, 90-kDa - metabolism Signal Transduction - drug effects sodium glucose co-transporter 2 inhibitors (SGLT2i) sodium hydrogen exchanger 1 (NHE1) Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Hydrogen Exchanger 1 - antagonists & inhibitors Sodium-Hydrogen Exchanger 1 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!